Benjamin F. McGraw, III
2021
In 2021, Benjamin F. McGraw, III earned a total compensation of $1.3M as Former Interim Executive Chair at Aerie Pharmaceuticals.
Compensation breakdown
| Option Awards | $670,303 |
|---|---|
| Salary | $172,727 |
| Stock Awards | $428,373 |
| Other | $70,355 |
| Total | $1,341,758 |
McGraw received $670.3K in option awards, accounting for 50% of the total pay in 2021.
McGraw also received $172.7K in salary, $428.4K in stock awards and $70.4K in other compensation.
Rankings
In 2021, Benjamin F. McGraw, III's compensation ranked 7,696th out of 12,405 executives tracked by ExecPay. In other words, McGraw earned more than 38.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,696 out of 12,405 | 38th |
Division Manufacturing | 3,389 out of 5,494 | 38th |
Major group Chemicals And Allied Products | 1,501 out of 2,369 | 37th |
Industry group Drugs | 1,335 out of 2,090 | 36th |
Industry Biological Products, Except Diagnostic Substances | 306 out of 452 | 32nd |
Source: SEC filing on April 26, 2022.
McGraw's colleagues
We found seven more compensation records of executives who worked with Benjamin F. McGraw, III at Aerie Pharmaceuticals in 2021.
2021
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
2021
Raj Kannan
Aerie Pharmaceuticals
Chief Executive Officer
2021
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
2021
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
2021
John LaRocca
Aerie Pharmaceuticals
General Counsel
2021
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
2021
Christopher Staten
Aerie Pharmaceuticals